Download Full Text (854 KB)



- Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease that leads to significant morbidity and mortality. Magnesium deficiency is known to lead to increased risk of both respiratory and cardiovascular diseases1. This deficiency can lead to an inflammatory state and increased bronchoconstriction that would exacerbate a disease state like COPD.2 Magnesium deficiency is seen in aging populations and those with chronic diseases3 and has also been seen in the population of patients coming into the emergency room with acute exacerbations of COPD.4

- Treatment with IV magnesium has been shown to be efficacious in treating COPD exacerbations,5 but there is new research investigating oral Magnesium in stable phase COPD patients to prevent acute exacerbations to help improve the quality of life of patients managing this chronic condition.6

- Current standard of care for COPD includes short acting beta agonists, muscarinic blockers, and inhaled glucocorticoids.

- The theorized pathophysiology of magnesium includes an antagonism of calcium which blocks channels and prevents the release of acetylcholine on the neuromuscular plate. This prevents constriction of bronchial smooth muscle, instead allowing for bronchodilation

Publication Date



magnesium, COPD exacerbations


Medicine and Health Sciences | Pulmonology


Capstone presentations were completed in partial fulfillment of the Master of Science degree in Physician Assistant Studies at Thomas Jefferson University.

Document Type


In Stable Phase COPD Patients does Oral Magnesium Supplementation vs Nothing Decrease the Number of COPD Related Hospitalizations?

Included in

Pulmonology Commons